SCHEMBL4676293

SCHEMBL4676293

O=C(C=C(O)c1nn[nH]n1)c1ccc(S(=O)(=O)c2ccc(F)cc2)s1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 4/20 0.33
LMNA P02545 2/20 0.33
PPARG P37231 1/20 0.33
NCOA2 Q15596 1/20 0.33
NCOA1 Q15788 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NCOA3 Q9Y6Q9 1/20 0.33
MAOA P21397 1/20 0.31
LOX P28300 1/20 0.31
AKR1B1 P15121 1/20 0.31
MEN1 O00255 1/20 0.31
MITF O75030 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
CASP6 P55212 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
IKBKB O14920 1/20 0.30
HTR2A P28223 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672177 0.89 TDP1 (0.34) LMNAPPARGNCOA2NCOA1NPSR1
SCHEMBL4680056 0.86 MAPT (0.35) LMNAAKR1B1MEN1MITFALDH1A1
SCHEMBL4677761 0.83 LMNA (0.35) CFTRLMNAPPARGNCOA2NCOA1
SCHEMBL4675170 0.81 PTGDR2 (0.32) CFTRAKR1B1CXCR3
SCHEMBL4672382 0.78 NPSR1 (0.41) LMNANPSR1AKR1B1MEN1MITF
SCHEMBL4673518 0.78 IKBKB (0.32) LMNAAKR1B1MEN1MITFALDH1A1
SCHEMBL4672683 0.78 MEN1 (0.34) LMNAAKR1B1MEN1MITFALDH1A1
SCHEMBL4671570 0.78 PTGDR2 (0.32) AKR1B1MAPTCXCR3
SCHEMBL4675639 0.77 ALOX5 (0.34) LMNAMEN1ALDH1A1MAPTKMT2A
SCHEMBL4676313 0.77 AKR1B1 (0.34) AKR1B1MEN1KMT2AHTR2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CFTR 3324/4885LMNA 659/4885PPARG 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.